Abiomed Inc. (NASDAQ:ABMD)

Total revenue exhibited a strong upward trajectory from March 31, 2017, to March 31, 2022, increasing from US$ 445.3 million to US$ 1.03 billion. The overall growth reflects a substantial expansion of market presence over the six-year period, characterized by a growth pattern that culminated in the breach of the billion-dollar revenue threshold in the final fiscal year analyzed.

Product Revenue Performance

Product revenue served as the primary driver of financial growth, rising from US$ 423.7 million in 2017 to US$ 984.5 million in 2022. Rapid expansion was observed between 2017 and 2020, followed by a period of stagnation between 2020 and 2021, during which revenue remained virtually flat at approximately US$ 806 million. This plateau was subsequently followed by a robust recovery in 2022, with an increase of approximately 22%.

Service and Other Revenue Trends

Service and other revenue demonstrated consistent and uninterrupted growth throughout the analyzed period. Starting at US$ 21.6 million in 2017, this segment grew every year to reach US$ 47.2 million by 2022. This steady climb suggests an expanding installed base of products requiring ongoing support and services, providing a more predictable and stable revenue stream compared to the volatility observed in product sales.

Revenue Stream Composition

The revenue mix remained heavily weighted toward product sales, which consistently accounted for the vast majority of total revenue. While service revenue more than doubled in absolute terms over the period, its relative contribution to total revenue remained secondary, although its consistent growth indicates a gradual diversification of the income base.